病毒载体生产市场－全球产业规模、份额、趋势、机会和预测，按载体类型、工作流程、应用、最终用户、地区和竞争情况细分，2020 年至 2030 年

2024年全球病毒载体生产市场价值为67.1亿美元，预计2030年将达到159.2亿美元，预测期间的复合年增长率为15.45%。病毒载体生产涉及开发工程病毒，用作载体将遗传物质递送至目标细胞，用于治疗或研究目的。这些载体在基因治疗、基因编辑和疫苗开发中发挥重要作用，为治疗遗传疾病和癌症提供了精准的手段。该过程需要修改病毒基因组以消除致病特性并整合治疗基因。主要的病毒载体包括腺相关病毒 (AAV)、慢病毒、腺病毒和逆转录病毒，每种载体的选择均基于预期用途、目标细胞类型和所需的表达谱。已获批准的基因疗法日益成功以及研发投入的不断增加，正在加速对高品质、可扩展病毒载体製造的需求，从而推动该领域的显着增长。

关键市场驱动因素

病毒载体生产的开创性临床成功

主要市场挑战

可扩展性和商业化

主要市场趋势

製造流程优化

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球病毒载体生产市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按载体类型（腺病毒、AAV、慢病毒、逆转录病毒等）
  • 依工作流程（上游处理、载体扩增及扩展、载具回收/收穫、下游处理、纯化、填充完成）
  • 按应用（基因和细胞疗法开发、疫苗开发、生物製药和药物发现、生物医学研究）
  • 按最终用户（製药和生物製药公司、研究机构）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美病毒载体生产市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲病毒载体生产市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太染料市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国病毒载体生产市场
  • 印度病毒载体生产市场
  • 韩国病毒载体生产市场
  • 日本病毒载体生产市场
  • 澳洲病毒载体生产市场

第九章：南美病毒载体生产市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲病毒载体生产市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Merck KGaA
• FUJIFILM Diosynth Biotechnologies USA
• Cobra Biologics Ltd.
• Thermofisher Scientific Inc.
• Waisman Biomanufacturing
• Genezen Laboratories
• Advanced BioScience Laboratories, Inc. (ABL inc.)
• Novasep Holding sas
• Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
• Takara Bio Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Viral Vector Production Market was valued at USD 6.71 billion in 2024 and is anticipated to reach USD 15.92 billion by 2030, growing at a CAGR of 15.45% during the forecast period. Viral vector production involves the development of engineered viruses used as carriers to deliver genetic material into targeted cells for therapeutic or research purposes. These vectors are instrumental in gene therapy, gene editing, and vaccine development, offering precision in treating genetic disorders and cancers. The process entails modifying viral genomes to eliminate pathogenic properties and incorporate therapeutic genes. Key viral vectors include adeno-associated viruses (AAV), lentiviruses, adenoviruses, and retroviruses, each selected based on the intended application, target cell type, and required expression profile. The growing success of approved gene therapies and increasing R&D investments are accelerating demand for high-quality, scalable viral vector manufacturing, driving significant growth in this segment.

Key Market Drivers

Pioneering Clinical Success of Viral Vector Production

The clinical success of gene therapies leveraging viral vectors has played a critical role in driving market growth. Breakthroughs such as Luxturna, approved by the FDA for treating Leber congenital amaurosis (LCA), and Zolgensma for spinal muscular atrophy (SMA), underscore the transformative potential of viral vector-based treatments. Zolgensma alone has treated over 3,000 patients globally as of 2023. Additionally, promising advancements in hemophilia B treatments, utilizing AAV vectors to restore clotting factor IX levels, highlight the clinical viability of these delivery tools. Lentiviral vectors have also been widely adopted in CAR-T cell therapies targeting blood cancers. These successes demonstrate the therapeutic efficacy, safety, and long-term benefits of viral vectors, prompting increased investment and adoption across both academic and commercial sectors.

Key Market Challenges

Scalability and Commercialization

Scaling up viral vector production for commercial use poses significant operational and financial hurdles. Transitioning from lab-scale to large-scale manufacturing requires overcoming challenges such as maintaining yield consistency, optimizing cell culture conditions, and controlling vector integrity under scaled processes. High-yield production must address issues related to oxygen transfer, nutrient delivery, and shear stress in bioreactors. Additionally, ensuring quality and stability of viral vectors during purification and fill-finish steps is essential but complex. Building compliant manufacturing facilities requires large capital investment and adherence to strict regulatory standards. These scale-related constraints delay commercialization timelines, increase production costs, and limit patient access to advanced therapies, especially when demand accelerates.

Key Market Trends

Manufacturing Process Optimization

Process optimization is a critical trend shaping the viral vector production landscape. Industry players are focusing on increasing yield, consistency, and scalability through innovations in upstream and downstream workflows. Efforts include enhancing cell line productivity, refining transfection protocols, and automating quality control. Manufacturers are standardizing production processes to ensure reproducibility across facilities, which aids in regulatory compliance and technology transfer. Moreover, improvements in purification and fill-finish steps are helping reduce impurities and boost product quality. Environmentally sustainable manufacturing approaches-such as reducing waste and energy usage-are also gaining prominence. These optimizations not only lower production costs but also ensure that therapies reach patients more efficiently and reliably.

Key Market Players

• Merck KGaA
• FUJIFILM Diosynth Biotechnologies U.S.A
• Cobra Biologics Ltd.
• Thermo Fisher Scientific Inc.
• Waisman Biomanufacturing
• Genezen Laboratories
• Advanced BioScience Laboratories, Inc. (ABL Inc.)
• Novasep Holding S.A.S.
• Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech Ltd.)
• Takara Bio Inc.

Report Scope:

In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector Production Market, By Vector Type:

• Adenovirus
• AAV
• Lentivirus
• Retrovirus
• Others

Viral Vector Production Market, By Workflow:

• Upstream Processing
• Vector Amplification and Expansion
• Vector Recovery/Harvesting
• Downstream Processing
• Purification
• Fill Finish

Viral Vector Production Market, By Application:

• Gene and Cell Therapy Development
• Vaccine Development
• Biopharmaceutical and Pharmaceutical Discovery
• Biomedical Research

Viral Vector Production Market, By End User:

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vector Production Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector Production Market.

Available Customizations:

Global Viral Vector Production Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector Production Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others)
  • 5.2.2. By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish)
  • 5.2.3. By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research)
  • 5.2.4. By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Viral Vector Production Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vector Type
  • 6.2.2. By Workflow
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Viral Vector Production Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vector Type
      • 6.3.1.2.2. By Workflow
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Viral Vector Production Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vector Type
      • 6.3.2.2.2. By Workflow
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Viral Vector Production Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vector Type
      • 6.3.3.2.2. By Workflow
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Viral Vector Production Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vector Type
  • 7.2.2. By Workflow
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Viral Vector Production Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vector Type
      • 7.3.1.2.2. By Workflow
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Viral Vector Production Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vector Type
      • 7.3.2.2.2. By Workflow
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Viral Vector Production Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vector Type
      • 7.3.3.2.2. By Workflow
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Viral Vector Production Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vector Type
      • 7.3.4.2.2. By Workflow
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Viral Vector Production Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vector Type
      • 7.3.5.2.2. By Workflow
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Viral Vector Production Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vector Type
  • 8.2.2. By Workflow
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Viral Vector Production Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vector Type
      • 8.3.1.2.2. By Workflow
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Viral Vector Production Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vector Type
      • 8.3.2.2.2. By Workflow
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Viral Vector Production Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vector Type
      • 8.3.3.2.2. By Workflow
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Viral Vector Production Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vector Type
      • 8.3.4.2.2. By Workflow
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Viral Vector Production Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vector Type
      • 8.3.5.2.2. By Workflow
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Viral Vector Production Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vector Type
  • 9.2.2. By Workflow
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Viral Vector Production Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vector Type
      • 9.3.1.2.2. By Workflow
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Viral Vector Production Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vector Type
      • 9.3.2.2.2. By Workflow
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Viral Vector Production Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vector Type
      • 9.3.3.2.2. By Workflow
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Viral Vector Production Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vector Type
  • 10.2.2. By Workflow
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Viral Vector Production Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vector Type
      • 10.3.1.2.2. By Workflow
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Viral Vector Production Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vector Type
      • 10.3.2.2.2. By Workflow
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Viral Vector Production Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vector Type
      • 10.3.3.2.2. By Workflow
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. FUJIFILM Diosynth Biotechnologies U.S.A
• 15.3. Cobra Biologics Ltd.
• 15.4. Thermofisher Scientific Inc.
• 15.5. Waisman Biomanufacturing
• 15.6. Genezen Laboratories
• 15.7. Advanced BioScience Laboratories, Inc. (ABL inc.)
• 15.8. Novasep Holding s.a.s.
• 15.9. Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
• 15.10. Takara Bio Inc.

16. Strategic Recommendations

17. About Us & Disclaimer